Novartis (NOVN) PT Set at CHF 87 by Kepler Capital Markets

Kepler Capital Markets set a CHF 87 target price on Novartis (VTX:NOVN) in a research note published on Tuesday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently weighed in on NOVN. Goldman Sachs Group set a CHF 110 price target on shares of Novartis and gave the stock a buy rating in a report on Monday, March 25th. UBS Group set a CHF 89 price target on shares of Novartis and gave the stock a neutral rating in a report on Monday, March 4th. JPMorgan Chase & Co. set a CHF 85 price target on shares of Novartis and gave the stock a sell rating in a report on Tuesday, February 26th. HSBC set a CHF 86 price target on shares of Novartis and gave the stock a neutral rating in a report on Wednesday, February 6th. Finally, Deutsche Bank set a CHF 93 price target on shares of Novartis and gave the stock a neutral rating in a report on Tuesday, February 5th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of CHF 88.41.

Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: How can you know how many shares are floating?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.